Magnesio Solfato S.A.L.F (Magnesium Sulfate Heptahydrate)

The compound releases magnesium ions that act as calcium antagonists, stabilising neuronal membranes, reducing excitability, and causing vasodilation. In the heart, magnesium influences ion channels and the Na⁺/K⁺‑ATPase pump, helping to normalise cardiac rhythm and prevent abnormal electrical activity.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function and therapeutic goal. Healthcare professionals follow local guidelines and adjust the regimen according to laboratory monitoring and clinical response.

Magnesium sulfate is classified as a pregnancy category that is used only when clearly indicated, such as for eclamptic seizure prevention. It may be administered under obstetric supervision. Limited data are available for breastfeeding, and the decision should be made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Magnesio Solfato provides magnesium as a sterile injectable solution, allowing rapid correction of severe deficiency and precise control in acute settings. Oral magnesium salts are slower acting and may cause gastrointestinal irritation, while other injectable forms may differ in concentration or stabilisers. Choice depends on clinical urgency, route preference and patient tolerance.

The product should be stored at controlled room temperature, typically between 20 °C and 25 °C, in its original packaging. Protect it from direct light, moisture and extreme temperatures. Do not freeze. Inspect the vial for particulate matter or discoloration before use.

Magnesio Solfato is supplied as a sterile solution for intramuscular or intravenous injection. The route, infusion speed and dilution are determined by the prescriber. Intravenous administration is usually performed via a controlled infusion pump, while intramuscular injection follows standard aseptic techniques.

Serious risks include respiratory depression, severe hypotension, cardiac arrest, hypermagnesemia with resultant cardiac conduction abnormalities, and rare anaphylactic reactions. Continuous monitoring of vital signs and serum magnesium levels is essential, especially in patients with renal impairment or cardiac disease.

Magnesio Solfato is contraindicated in patients with known hypersensitivity to magnesium sulfate, severe renal failure where magnesium clearance is markedly reduced, and in those with existing hypermagnesemia. Caution is also advised for individuals with myasthenia gravis or other neuromuscular disorders.